A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma

NCT00034151 Phase 2 COMPLETED

Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or primary peritoneal carcinoma.

Details

Lead sponsor	Achieve Life Sciences
Phase	Phase 2
Status	COMPLETED
Enrolment	52
Start date	2002-03
Completion	2007-09

Conditions

• Ovarian Cancer

Interventions

• S-8184 Paclitaxel Injectable Emulsion

Primary outcomes

• Determine the objective and partial response rates — No time frame-based on number of patients